Brofaromine

From Wikipedia, the free encyclopedia

Brofaromine
Systematic (IUPAC) name
4-(7-bromo-5-methoxy-1-benzofuran-2-yl)piperidine
Identifiers
CAS number 63638-91-5
ATC code  ?
PubChem 44571
Chemical data
Formula C14H16BrNO2 
Mol. mass 310.186 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding 98%
Metabolism  ?
Half life 9 to 14 hours
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes Oral

Brofaromine is a reversible inhibitor of monoamine oxidase A primarily useful in the treatment of depression and anxiety. It is not commercially available and is not being actively researched, possibly due to a lack of financial interest.[1]

[edit] Pharmacology

Brofaromine is a reversible inhibitor of monoamine oxidase A (RIMA, a type of monoamine oxidase inhibitor (MAOI)) and acts on epinephrine (adrenaline), norepinephrine (noradrenaline), serotonin, and dopamine. Unlike standard MAOIs, possible side effects do not include cardiovascular complications (hypertension) with encephalopathy, liver toxicity or hyperthermia.

[edit] References

  1. ^ Lotufo-Neto F, Trivedi M, Thase ME (1999). "Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression". Neuropsychopharmacology 20 (3): 226–47. doi:10.1016/S0893-133X(98)00075-X. PMID 10063483.  Free full text


Languages